Medicinal application of novel recombinant human interleukin-1 receptor antagonist
A technology of interleukin and receptor antagonists, which is applied in the field of medicinal use of new recombinant human interleukin-1 receptor antagonists, can solve problems such as adverse reactions, and achieve pain relief, stable quality, and patient good compliance
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0019] The amino acid sequence of rhIL-1Ra described in this application is shown in SEQ ID NO: 1, and its preparation method is as follows: the recombinant human interleukin-1 receptor antagonist of the present invention is constructed by using Escherichia coli expression technology to contain interleukin -1 receptor antagonist gene recombinant plasmid, and transformed into Escherichia coli to obtain stable engineered bacteria, engineering bacteria purified after fermentation to obtain recombinant human interleukin-1 receptor antagonist stock solution, adding auxiliary materials to make recombinant human interleukin-1 receptor antagonist stock solution Primer-1 receptor antagonist injection.
Embodiment 2
[0020] Embodiment 2: Pharmacodynamics test
[0021] The present inventor observed the therapeutic effect of rhIL-1Ra on sodium urate-induced acute gout in rats with 60 female SD rats.
[0022] method:
[0023] After the quarantine period of 60 female SD rats, the thermal pain threshold and the basic value of the ankle joint diameter of the right hindlimb were measured, and they were divided into balanced groups according to the thermal pain threshold, and 10 normal control animals and 50 model group animals were separated. On the second day, the model group was anesthetized with isoflurane and injected 50 μL of sodium urate (25 mg / mL, prepared in normal saline) into the articular cavity at the rear of the ankle joint of the right hind limb along the medial side of the Achilles tendon at 30-40°. The same volume of normal saline was injected in the group, and the ankle joint diameter and thermal pain threshold of the right hindlimb were measured 3 hours after the model was esta...
Embodiment 3
[0039] Embodiment 3: pharmacological test
[0040] The present inventors observed a wide range of pharmacological effects of rhIL-1Ra in addition to the biopharmaceutical effects of acute gout in mice and cats.
[0041] method:
[0042] 1. Get mice with a body weight of 18-22g, half male and half male, and randomly divide them into 4 groups, 10 mice in each group, and divide them into solvent control model group, low-dose raw material drug group (4.5mg / kg), medium-dose raw material drug group (9mg / kg) / kg) and the high-dose group of raw material drug (18mg / kg). After subcutaneous injection, observe the general behavior, posture, gait of the mice, whether there is tremor or paralysis, whether there is appetite, whether there is incontinence of urine and urine, etc. changes. And record respectively 2 minutes before the administration and 30 minutes after the administration, the walking time of the mice and the number of liftings on both forelimbs.
[0043] 2. Get cats with a ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More - R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com